跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AML-3
首页
药物
AML-3
AML-3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
申请人: WYETH CORP
优先权: 2007
US
Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
申请人: UNIV PENNSYLVANIA
优先权: 2020
US
2 件公开
Method for researching resistance effect and mechanism of AML exosome on AML chemotherapy
申请人: WUXI ZHUNYIN BIO TECH CO LTD
优先权: 2020
CN
Drug for treating AML and application of drug
申请人: ZENG HUI
优先权: 2019
CN
Methods of treating acute myeloid leukemia with an FLT3 mutation
申请人: BIOKINE THERAPEUTICS LTD
优先权: 2013
CN
COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
申请人: RHIZEN PHARMACEUTICALS AG
优先权: 2019
CN
EP
US
WO
4 件公开
Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
申请人: HANMI PHARMACEUTICAL CO LTD
优先权: 2019
US
PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA
申请人: HANMI PHARMACEUTICAL CO LTD
优先权: 2019
CN
EP
2 件公开
药物
反馈